Evaluation of polypharmacy and its effects in geriatric age group patients applying to the internal diseases outpatient clinic
Polypharmacy and geriatry
Keywords:Drug-drug interaction, geriatrics, polypharmacy
Objective: The world population is aging and the elderly population is trying to cope with chronic diseases and multiple drug use. Polypharmacy can be defined as the combined use of four or more drugs. Pharmacokinetic and pharmacodynamic changes of drugs and drug-drug interactions in old age may affect this age group much more. In the study, it was aimed to determine the levels of drug interactions in geriatric age group patient prescriptions.
Methods: In this study, drug-drug interactions were investigated in outpatients over the age of 65 who had 4 or more drugs prescribed. A total of 119 prescriptions were included in the study. The average number of drugs in prescriptions is 5.23 (min 4 max 12).
Results: No statistically significant difference was found between the mean age of men and women in the study. The group of drugs that interact most frequently is antidiabetic drugs. In second place are diuretics and nonsteroidal anti-inflammatory drugs (NSAIDs); angiotensin converting enzyme (ACE) inhibitor drugs are in the third place.
Conclusion: Prevention of polypharmacy and its related problems will benefit both the patient and the cost. By avoiding polypharmacy or at least by following guidelines when prescribing, geriatric patients' drug compliance will increase, all side effects and interactions that may be caused by inappropriate drug use will be kept to a minimum, and possible hospitalizations and health expenses will be reduced in this way.
United States Department of Health and Human Services, 2001. A profile of older Americans: 2001. Administration on Aging. http://www.caregiverslibrary.org/ (Accessed 12/11/21)
Kalache A, Gatti A. Active ageing: a policy framework. Adv Gerontol. 2003;11:7-18.
Medicines and older people: implementing medicines-related aspects of the NSF for older people, 2001. http://www.wales.nhs.uk/sites3/documents/ (Accessed: 26/12/21)
Morin L, Johnell K, Laroche ML, Fastbom J, Wastesson JW. The epidemiology of polypharmacy in older adults: register-based prospective cohort study. Clinical epidemiology. 2018;10:289.
Thapaliya K, Harris ML, Byles JE. Polypharmacy trajectories among older women with and without dementia: A longitudinal cohort study. Explor Res ClinSoc Pharm. 2021;3:100053.
Davies LE, Kingston A, Todd A, Hanratty B. Characterisingpolypharmacy in the very old: Findings from the Newcastle 85+ Study. PLoS One. 2021;16(1):e0245648.
Nobili A, Tettamanti M, Frattura L, Spagnoli A, Ferraro L, Marrazzo E et al. Drug use by the elderly in Italy. Ann Pharmacother. 1997;31(4):416-22.
Rollason V, Vogt N. Reduction of polypharmacy in the elderly: a systematic review of the role of the pharmacist. Drugs Aging. 2003;20(11):817-32.
Vatcharavongvan P, Puttawanchai V. Elderly Patients in Primary Care are Still at Risks of Receiving Potentially Inappropriate Medications. J Prim Care Community Health. 2021;12:21501327211035088.
Liao SH, Hu SY, How CK, Hsieh VC, Chan CM, Chiu CS et al. Risk for hypoglycemic emergency with levofloxacin use, a population-based propensity score matched nested case-control study. PLoS One. 2022;17(4):e0266471.
Berhe A, Russom M, Bahran F, Hagos G. Ciprofloxacin and risk of hypolycemia in non-diabetic patients. J Med Case Rep. 2019;13(1):142.
Şen S, Karahan E, Büyükulaş C, Polat YO, Üresin AY. Colchicine for cardiovascular therapy: A drug interaction perspective and a safety meta-analysis. Anatol J Cardiol. 2021;25(11):753-61.
Lomaestro BM, Bailie GR. Quinolone-cation interactions: a review. DICP. 1991;25(11):1249-58.
Ruscica M, Baldessin L, Boccia D, Racagni G, Mitro N. Non-insulin anti-diabetic drugs: An update on pharmacological interactions. Pharmacol Res. 2017;115:14-24.
Sinclair AJ, Davies IB, Warrington SJ. Betaxolol and glucose-insulin relationships: studies in normal subjects taking glibenclamide or metformin. Br J ClinPharmacol. 1990;30(5):699-702.
Deng J, Zhu X, Chen Z, Fan CH, Kwan HS, Wong CH et al. A Review of Food-Drug Interactions on Oral Drug Absorption. Drugs. 2017;77(17):1833-55.
de Vries M, Seppala LJ, Daams JG, van de Glind EMM, Masud T, van der Velde N; EUGMS Task and Finish Group on Fall-Risk-Increasing Drugs. Fall-Risk-Increasing Drugs: A Systematic Review and Meta-Analysis: I. Cardiovascular Drugs. J Am Med Dir Assoc. 2018;19(4):371-9
Kardas P, Urbański F, Lichwierowicz A, Chudzyńska E, Czech M, Makowska K et al. The Prevalence of Selected Potential Drug-Drug Interactions of Analgesic Drugs and Possible Methods of Preventing Them: Lessons Learned From the Analysis of the Real-World National Database of 38 Million Citizens of Poland. Front Pharmacol. 2021;11:607852.
Samardzic I, Bacic-Vrca V. Incidence of potential drug-drug interactions with antidiabetic drugs. Pharmazie. 2015;70(6):410-5.
Kim J, Ahn CW, Fang S, Lee HS, Park JS. Association between metformin dose and vitamin B12 deficiency in patients with type 2 diabetes. Medicine (Baltimore). 2019;98(46):e17918.
Hee Nam Y, Brensinger CM, Bilker WB, Flory JH, Leonard CE, Hennessy S. Angiotensin-Converting Enzyme Inhibitors Used Concomitantly with Insulin Secretagogues and the Risk of Serious Hypoglycemia. Clin Pharmacol Ther. 2022;111(1):218-26.
Scalbert E, Abdon D, Devissaguet M, Juggi JS. Interaction between an angiotensin converting enzyme inhibitor, perindopril, and a thiazide diuretic in the spontaneously hypertensive rat. Can J Cardiol. 1992;8(4):381-6.
Nii K, Morinaga Y, Mitsutake T, Inoue R, Higashi T. Different Clopidogrel Response Elicited by Lansoprazole or Esomeprazole in Patients Undergoing Neurointervention with Dual Antiplatelet Therapy. Clin Drug Investig. 2019;39(10):939-944.
Brie DM, Mornos C, Brie DA, Luca CT, Petrescu L, Boruga M. Potential role for pentoxifylline as an anti-inflammatory drug for patients with acute coronary syndrome. Exp Ther Med. 2022;23(6):378.
Kim MS, Song HJ, Lee J, Yang BR, Choi NK, Park BJ. Effectiveness and Safety of Clopidogrel Co-administered With Statins and Proton Pump Inhibitors: A Korean National Health Insurance Database Study. Clin Pharmacol Ther. 2019;106(1):182-94.
Humphrey ML, Barkhordari N, Kaakeh Y. Effects of Omeprazole on Vitamin and Mineral Absorption and Metabolism. Journal of Pharmacy Technology. 2012;28(6):243-8.
Govener T, Brand M. Adverse gastrointestinal bleeding associated with over the counter non-steroidal anti-inflammatory drug use: A cost study in two Gauteng public hospitals. South African Gastroenterology Review. 2022;20.2: 7-10.
Wuehler S, Lopez de Romaña D, Haile D, McDonald CM, Brown KH. Reconsidering the Tolerable Upper Levels of Zinc Intake among Infants and Young Children: A Systematic Review of the Available Evidence. Nutrients. 2022;14(9):1938.
Turkish Pharmaceutical Market Observation Report, 2019. https://titck.gov.tr/storage/Archive/2019/.pdf (Accessed 24/12/21)
Antimicrobial Resistance Polict Insight, 2016. https://www.oecd.org/health/health-systems/AMR-Policy-Insights November2016.pdf (Accessed 24/12/21)
Masoodi N. Polypharmacy: To err is human, to correct divine. Br J Clin Pharmacol 2008;1:6–9.
American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2012; 60(4):616-31.
Bahat G, Ilhan B, Erdogan T, Oren MM, Karan MA, Burjhardt H et al. Turkish inappropriate medication use in the elderly (TIME) criteria to improve prescribing in older adults: TIME-to-STOP/TIME-to-START. Eur Geriatr Med. 2020;11(3):491-8.
Yüksel H, Kaplan İ, Toprak G, Evliyaoğlu O, Kuş S, Azizoğlu M, et al. A questionnaire study among nurses: awareness of blood and urine sample collection procedures. Clin Chem Lab Med. 2014;52(8):e159-61.
Dicleli M, Alabalık U, Bıçak T, Yıldız G, Sertakan H, Nacir M. Plasmacytoma: A Rare Case of Bone Malignancy. J Clin Tri Exp Invest. 2022; 1(1), 17–21.
Pagotti MD, Bueno SCP, Gomes CIG, de Oliveira PA, Scanavacca MI, Hachul DT. The Importance of Adequate Programming Dual-Chamber Pacemaker in Physically Active Patients. J Clin Tri Exp Invest. 2022;1(1), 22–7.
How to Cite
Copyright (c) 2022 The Injector
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.